Thomas I. H. Dubin
About Thomas I. H. Dubin
Thomas I. H. Dubin (age 62) is a pharmaceutical executive and attorney who joined the Intensity Therapeutics (INTS) board in May 2024 as an independent director. He previously served as Chief Legal Officer and a core executive at Alexion Pharmaceuticals (2001–2013), and holds a J.D. from NYU, an M.P.H. from Yale, and a B.A. from Amherst College (cum laude) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Alexion Pharmaceuticals | Chief Legal Officer; core executive team; led legal, government affairs, pricing/reimbursement, HR, corp comms; commercial lead for Australasia | 2001–2013 | Helped grow from development stage to S&P 500 membership |
| ChiRex, Inc. | Vice President and General Counsel | Not disclosed | Legal leadership |
| Warner-Lambert Company | Assistant General Counsel | Not disclosed | Legal counsel |
| Cravath, Swaine & Moore | Corporate attorney | Not disclosed | Corporate law practice |
External Roles
| Organization | Role | Status/Tenure | Type |
|---|---|---|---|
| Cellphire Therapeutics | Executive Chair | Current | Private biopharma |
| Notable Laboratories (Nasdaq: NTBL) | Board Member | Current | Public biopharma |
| Norwalk Hospital | Board Member | Current | Non-profit healthcare |
| Connecticut Innovations | Board Member | Current | State venture/innovation fund |
| Yale School of Public Health | Leadership Council Member | Current | Academic advisory |
| Mythic Pharmaceuticals | Advisory Board Member | Current | Private biopharma |
| BioBlast Pharmaceuticals (Nasdaq: ORPN) | Board Member | 2015–2018 | Public biopharma |
| American Jewish World Service | Trustee | 2014–2021 | Non-profit |
Board Governance
- Independence: The board determined Dubin is an “independent director” under Nasdaq rules .
- Committee assignments: Member, Audit Committee (Chair: Emer Leahy; Members: Mark A. Goldberg, Thomas I. H. Dubin) .
- Attendance: For FY2023, no director attended fewer than 75% of meetings; Dubin joined in May 2024 (attendance disclosure for 2023 reflects directors then in office) .
- Board structure: CEO also serves as Chair; the company does not have a Lead Independent Director; independent directors regularly have the opportunity to meet without the CEO .
- Other committees: Compensation (Donovan—Chair, Leahy, Goldberg); Nominating & Governance (Goldberg—Chair, Donovan). Dubin is not listed on these committees .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Board retainer (cash) | $40,000 | Non-employee director retainer |
| Audit Committee member fee (cash) | $10,000 | Member (Chair is $20,000) |
| Meeting fees | $0 | No meeting fees paid |
| Equity grants (directors) | Not specified in policy | Company disclosed no director equity awards were made in 2023; see Equity Ownership for Mr. Dubin’s option holdings |
Performance Compensation
| Performance metric(s) tied to director compensation | Disclosure |
|---|---|
| Any formulaic or discretionary performance metrics (e.g., TSR, revenue, ESG) | None disclosed for non-employee directors; 2023 director compensation was cash-based per policy |
Other Directorships & Interlocks
| Company | Exchange | Role | Potential Interlock/Relevance |
|---|---|---|---|
| Notable Laboratories | Nasdaq: NTBL | Board Member | No INTS-related business ties disclosed in proxy |
| BioBlast Pharmaceuticals (prior) | Nasdaq: ORPN | Former Board Member (2015–2018) | Historical; no current INTS ties disclosed |
No related-party transactions involving Mr. Dubin were disclosed; notable related-party items involved a services agreement with rareLife solutions, whose CEO is INTS director Daniel Donovan (not Dubin) .
Expertise & Qualifications
- Deep legal, compliance, and government affairs expertise across biopharma; led Alexion’s legal, pricing/reimbursement, and public policy functions during its scale-up into the S&P 500 .
- Broad executive leadership (HR, corporate communications, regional commercial P&L in Australasia), bringing cross-functional operating experience to Audit oversight .
- Governance experience across public and private boards; advanced academic credentials in law and public health (J.D., M.P.H.) supporting risk oversight and healthcare policy insight .
Equity Ownership
| Metric | May 31, 2024 | Aug 31, 2025 |
|---|---|---|
| Shares/Options beneficially owned (total) | 12,500 (all options exercisable within 60 days) | 37,500 (all options exercisable within 60 days) |
| Ownership % of outstanding | <1% | <1% |
| Options exercisable within 60 days | 12,500 | 37,500 |
| Options not exercisable within 60 days | 37,500 | 62,500 |
| Shares pledged as collateral | No pledging disclosed in proxy materials |
Governance Assessment
-
Strengths
- Independent director with substantial biopharma scaling experience (Alexion) and multi-functional leadership that is additive to Audit Committee risk oversight .
- Clear independence determination; no Dubin-specific related-party transactions disclosed .
- Meaningful option holdings with additional unvested options indicate aligned upside orientation, albeit still <1% beneficial ownership .
-
Watch items
- Board leadership: combined CEO/Chair, no Lead Independent Director—this places more weight on independent committee effectiveness and executive sessions for robust oversight .
- Multiple external commitments (public and private boards); no time/attendance issues disclosed for Dubin to date, but continued monitoring warranted .
-
RED FLAGS observed
- None disclosed specific to Mr. Dubin (no RPTs, no pledging, no attendance concerns reported for period disclosed) .